Biomarkers are becoming an essential part of clinical development, not least because they offer a faster alternative to the conventional drug development approach and the promise of safer drugs, in greater numbers, approved more quickly. Many of the failures happen late in clinical trials, with the consequence that expenditure in clinical drug development -already a mammoth effort requiring a huge amount of money, time, and patient is increasing. The ultimate vision is to have access to therapeutic fields, a better understanding of pathophysiology of diseases, thereby uncovering potential drug targets and biomarkers in the disease pathway. By finding molecular biomarkers of the disease, diagnosis could be improved and could reveal new information about the disease, by which a better chance for developing drugs is possible. Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. In this present review, biomarkers of various diseases were enlisted to highlight the overabundance of information necessary for clinicians and scientists to have a thorough understanding of biomarkers and its ability to improve treatment and reduce health-care costs which are potentially greater than in any other area of medical research.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.